BARD1 Polyclonal Antibody - BT-AP00836

BARD1 Polyclonal Antibody

Sizes: 20μL, 50μL, 100μL

Catalogue Numbers: BT-AP00836-20, BT-AP00836-50, BT-AP00836-100

Citations, Manuals and MSDS Available upon request.

Background: BARD1 encodes a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer. Multiple alternatively spliced transcript variants encoding different isoforms have been found for BARD1.

Research Areas: Epigenetics and Nuclear Signaling

Target Protein: BARD1

Applications: WB, IHC-p, ELISA

Reactivity: Human

Clonality: Polyclonal

Host: Rabbit

Isotype: IgG

Full Product Name: BARD1 Antibody

Immunogen: The antiserum was produced against synthesized peptide derived from human AMPK alpha around the phosphorylation site of Thr172. AA range:140-189

Storage: -20°C for 1 year

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Concentration: 1 mg/ml

Molecular Weight (Da): 86648

UniProt Accession: Human: Q99728; Mouse: O70445

Synonyms: BARD1; BRCA1-associated RING domain protein 1; BARD-1

GeneID: Human: 580

Research Use Only